Recent advances in the development of small molecule inhibitors of PTP1B for the treatment of insulin resistance and type 2 diabetes

Current Opinion in Drug Discovery and Development

Volumn 5, Issue 4, 2002, Pages 500-512

  Tobin, James F ^a   Tam, Steve ^a  

^a PFIZER INC   (United States)

Author keywords

Diabetes; Insulin resistance; Insulin sensitivity; Protein tyrosine phosphatases; PTP1B; Signa1 transduction; Small molecule

Indexed keywords

4 (PHOSPHONODIFLUOROMETHYL)PHENYLALANINE; 4' O [2 (2 FLUOROMALONYL)]TYROSINE; 5 CARBOXY 2 NAPHTHOIC ACID; 6 (PHOSPHONODIFLUOROMETHYL) 2 NAPHTHOIC ACID; ERTIPROTAFIB; INSULIN; ISIS 113715; ISIS 1137515; N [6 (PHOSPHONODIFLUOROMETHYL) 2 NAPHTHOYL]GLUTAMIC ACID; O MALONYLTYROSINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHENYL PHOSPHATE; PHOSPHORUS ACID DERIVATIVE; PROTEIN TYROSINE PHOSPHATASE 1B; PROTEIN TYROSINE PHOSPHATASE 1B INHIBITOR; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; ROSIGLITAZONE; TENTAGEL; UNCLASSIFIED DRUG; PROTEIN SYNTHESIS INHIBITOR; PROTEIN TYROSINE PHOSPHATASE;

BINDING AFFINITY; BINDING SITE; CRYSTAL STRUCTURE; DRUG MECHANISM; ENZYME ACTIVE SITE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACODYNAMICS; PROTEIN MOTIF; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; WEIGHT GAIN; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; ENZYMOLOGY; METABOLISM; METHODOLOGY; PHARMACEUTICS; PHYSIOLOGY;

ANIMALS; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN RESISTANCE; PROTEIN SYNTHESIS INHIBITORS; PROTEIN-TYROSINE-PHOSPHATASE; TECHNOLOGY, PHARMACEUTICAL;

EID: 0036654436     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (119)

1. Hunter T: Signaling - 2000 and beyond. Cell (2000) 100:113-127. An excellent review and introduction to the role of phosphorylation in signal transduction.
2. Saltiel AR, Kahn CR: Insulin signaling and the regulation of glucose and lipid metabolism. Nature (2001) 414:799-806.
3. Tonks NK, Neel BG: Combinatorial control of the specificity of protein tyrosine phosphatases. Curr Opin Cell Biol (2001) 13:182-195.
4. Hundahl-Møller NP, Iversen LF, Andersen HS, McCormack JG: Protein tyrosine phosphatases (PTPs) as drug targets: Inhibitors of PTP-1B for the treatment of diabetes. Curr Opin Drug Discovery Dev (2000) 3:527-540. One of the first and best reviews of the progress and challenges of developing phosphatase inhibitors, especially inhibitors of PTP1B, as drugs.
5. Saltiel AR: New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell (2001) 104:517-529.
6. Zimmet P, Alberti KGM, Shaw J: Global and societal implications of the diabetes epidemic. Nature (2001) 414:782-787.
7. Zhang Z-Y: Protein-tyrosine phosphatases: Biological function, structural characteristics, and mechanism of catalysis. Crit Rev Biochem Mol Biol (1998) 33:1-52.
8. Ramponi G: The low-Mr cytosolic phosphotyrosine protein phosphatases. Adv Prot Phosphates (1994) 8:1-25.
9. Zhang Z-Y, Wu L, Chen L: Transition state and rate-limiting step of the reaction catalyzed by the human dual-specificity phosphatase VHR. Biochemistry (1995) 34:16088-16096.
10. Pot DA, Dixon JE: A thousand and two protein tyrosine phosphatases. Biochem Biophys Acta (1992) 1136:35-43.
11. Charbonneau H, Tonks NK: 1002 protein phosphatases? Annu Rev Cell Biol (1992) 8:463-493.
12. Van Huijsduijen RH: Protein tyrosine phosphatases: Counting the trees in the forest. Gene (1998) 225:1-8.
13. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, Smith HO, Yandell M, Evans CA, Holt RA, Gocayne JD et at. The sequence of the human genome. Science (2001) 291:1304-1351. This paper provided a first look at the size of the phosphatase family in humans.
14. Hogenesch JB, Ching KA, Batalov S, Su AI, Walker JR, Zhou Y, Kay SA, Schultz PG, Cooke MP: A comparison of the Celera and Ensembl predicted gene sets reveals little overlap in novel genes. Cell (2001) 106:413-415. An important contribution to gene counting exercises based on the human genome sequence indicates that existing estimates of the total number of genes may be low.
15. Bell GI, Polonsky KS: Diabetes mellitus and genetically programmed defects in β-cell function. Nature (2001) 414:788-791.
16. Krueger NX, Steuli M, Saito H: Structural diversity and evolution of human receptor-like protein tyrosine phosphatase. EMBO J (1990) 9:3241-3252.
17. Streuli M, Krueger NX, Hall LR, Schlossman SF, Saito H: A new member of the immunoglobulin superfamily that has a cytoplasmic region homologous to the leukocyte common antigen. J Exp Med (1988) 168:1523-1530.
18. Tonks NK, Diltz CD, Fischer EH: Purification of the major protein-tyrosine-phosphatases of human placenta. J Biol Chem (1988) 263:6722-6730. This study initiated the field of protein tyrosine phosphatase research.
19. Norris K, Norris F, Kono DH, Vestergaard H, Pedersen O, Theofilopoulos AN, Møller NPH: Expression of protein-tyrosine phosphatases in the major insulin target tissues. FEBS Lett (1997) 415:243-248.
20. Ahmad F, Goldstein BJ: Purification, identification and subcellular distribution of three predominant protein-tyrosine phosphatase enzymes in skeletal muscle tissue. Biochem Biophys Acta (1995) 1248:57-69.
21. Cong LN, Chen H, Li Y, Lin CH, Sap J, Quon MJ: Overexpression of protein tyrosine phosphatase-α (PTP-α) but not PTP-κ inhibits translocation of GLUT4 in rat adipose cells. Biochem Biophys Res Commun (1999) 255:200-207.
22. Cicirelli MF, Tonks NK, Diltz, CD, Weiel JE, Fischer EH, Krebs EG: Microinjection of a protein tyrosine phosphatase inhibits insulin action on Xenopus oocytes. Proc Natl Acad Sci USA (1990) 87:5514-5518.
23. Ahmad F, Li P-M, Meyerovicht J, Goldstein BJ: Osmotic loading of neutralizing antibodies demonstrates a role for protein-tyrosine phosphatase 1B in negative regulation of the insulin action pathway. J Biol Chem (1995) 270:20503-20508.
24. Kulas DT, Zhang W-R, Goldstein BJ, Furlanetto RW, Mooney RA: Insulin receptor signaling is augmented by antisense inhibition of the protein tyrosine phosphatase LAR. J Biol Chem (1995) 270:2435-2438.
25. Su J, Muranjan M, Sap J: Receptor protein tyrosine phosphatase alpha activates Src-family kinases and controls integrin-mediated responses in fibroblasts. Curr Biol (1999) 9:505-511.
26. Ren J-M, Li P-M, Zhang W-R, Sweet LJ, Cline G, Shulman GI, Livingston JN, Goldstein BJ: Transgenic mice deficient in the LAR protein-tyrosine phosphatase exhibit profound defects in glucose homeostasis. Diabetes (1998) 47:493-497.
27. Schaapveld RQJ, Schepens JTG, Robinson GW, Attema J, Oerlemans FRJJ, Fransen JAM, Streuli M, Wieringa B, Hennighausen L, Hendriks WJAJ: Impaired mammary gland development and function in mice lacking LAR receptor-like tyrosine phosphatase activity. Dev Biol (1997) 188:134-146.
28. Elchebly M, Payette P, Michaliszyn E, Cromlish W, Collins S, Loy AL, Normandin D, Cheng A, Himms-Hagen J, Chan CC, Ramachandran C, Gresser MJ, Tremblay ML, Kennedy BP: Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science (1999) 283:1544-1548. Along with reference [29], these papers represent two of the most important in PTB1B research. This paper indicated the desirability of inhibiting PTB1B in vivo for the treatment of diabetes.
29. Klaman LD, Boss O, Peroni OD, Kim JK, Martino JL, Zabolotny JM, Moghal N, Lubkin M, Kim YB, Sharpe AH, Stricker-Krongrad A, Shulman GI, Neel BG, Kahn BB: Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Mol Cell Biol (2000) 20:5479-5489. Along with reference [28], this paper directed the drug industry's focus towards PTP1B as a target for metabolic disease intervention.
30. Flint AJ, Tiganis T, Barford D, Tonks NK: Development of "substrate-trapping" mutants to identify physiological substrates of protein tyrosine phosphatases. Proc Natl Acad Sci USA (1997) 94:1680-1685.
31. Zabolotony JM, Bence-Hanulec KK, Stricker-Krongrad A, Haj F, Wang Y, Minokoshi Y, Kim Y-B, Elmquist JK, Tartaglia LA, Kahn BB, Neel BG: PTB1B regulates leptin signal transduction in vivo. Dev Cell (2002) 2:489-495
32. 2PmP. Biochem Biophys Res Commun (1994) 204:129-134.
33. Chen L, Wu L, Otaka A, Smyth MS, Roller PP, Burke TR Jr, den Hertog J, Zhang Z-Y: Why is phosphonodifluoromethyl phenylalanine a more potent inhibitory moiety than phosphonomethyl phenylalanine toward protein-tyrosine phosphatases? Biochem Biophy Res Commun (1995) 216:976-984.
34. Kole HK, Smyth MS, Russ PL, Burke TR Jr: Phosphonate inhibitors of protein-tyrosine and serine/threonine phosphatases. Biochemistry (1995) 311:1025-1031.
35. Taylor SD, Kotoris CC, Dinaut AN, Wang Q, Ramachandran C, Huang Z: Potent non-peptidyl inhibitors of protein tyrosine phosphatase 1B. Bioorg Med Chem (1998) 6:1457-1468.
36. Burke TR Jr, Ye B, Yan X, Wang S, Jia Z, Chen L, Zhang Z-Y, Barford D: Small molecule interactions with protein-tyrosine phosphatase PTP1B and their use in inhibitor design. Biochemistry (1996) 35:15989-15996.
37. Glover NR, Tracey AS: Nuclear magnetic resonance and restrained molecular dynamics studies of the interaction of an epidermal growth factor-derived peptide with protein tyrosine phosphatase 1B. Biochemistry (1999) 38:5256-5271.
38. Kotoris CC, Wen W, Lough A, Taylor SD: Preparation of chiral α-monofluoroalkyphosphonic acids and their evaluation as inhibitors of protein tyrosine phosphatase 1B. J Chem Soc Perkin Trans I (2000) 8:1271-1282.
39. Berkowitz DB, Bose M: ((α-Monofluoroalkyl)phosphonates: A class of isoacidic and 'tunable' mimics of biological phosphates. J Fluorine Chem (2001) 112:13-33.
40. Murthy VS, Kulkami VM: Molecular modeling of protein tyrosine phosphatase 1B (PTP1B) inhibitors. Bioorg Med Chem (2002) 10:897-906.
41. Yokomatsu T, Murano T, Umesue I, Soeda S, Shimeno H, Shibuya S: Synthesis and biological evaluation of α,αdifluorobenzylphosphonic acid derivatives as small molecular inhibitors of protein-tyrosine phosphatase 1B. Bioorg Med Chem Lett (1999) 9:529-532.
42. Kole HK, Akamatsu M, Ye B, Yan X, Barford D, Roller PP, Burke TR Jr. Protein-tyrosine phosphatase inhibition by a peptide containing the phosphotyrosyl mimetic, L-Omalonyltyrosine (L-OMT). Biochem Biophys Res Commun (1995) 209:817-822.
43. Burke TR Jr, Ye B, Akamatsu M, Ford H Jr, Yan X, Kole HK, Wolf G, Shoelson SE, Roller PP: 4′-O-[2-(2-fluoromalonyl)]-Ltyrosine: A phosphotyrosyl mimic for the preparation of signal transduction inhibitory peptides. J Med Chem (1996) 39:1021-1027.
44. Gao Y, Wu L, Luo JH, Guo R, Yang D, Zhang Z-Y, Burke TR Jr. Examination of novel non-phosphorus-containing phosphotyrosyl mimetics against protein-tyrosine phosphatase-1B and demonstration of differential affinities toward Grb2 SH2 domains. Bioorg Med Chem Lett (2000) 10:923-927.
45. Sarmiento M, Wu L, Keng Y-F, Song L, Luo Z, Huang Z, Wu GZ, Yuan AK, Zhang Z-Y: Structure-based discovery of small molecule inhibitors targeted to protein tyrosine phosphatase 1B. J Med Chem (2000) 43:146-155.
46. Gao Y, Voigt J, Zhao H, Pais GC, Zhang X, Wu L, Zhang Z-Y, Burke TR Jr. Utilization of a peptide lead for the discovery of a novel PTP1B-binding motif. J Med Chem (2001) 44(18):2869-2878.
47. Yao ZJ, Ye B, Wu XW, Wang S, Wu L, Zhang Z-Y, Burke TR Jr: Structure-based design and synthesis of small molecule protein-tyrosine phosphatase 1B inhibitors. Bioorg Med Chem (1998) 6:1799-1810.
48. Puius YA, Zhao Y, Sullivan M, Lawrence DS, Almo SC, Zhang ZY: Identification of a second aryl phosphate-binding site in protein-tyrosine phosphatase 1B: A paradigm for inhibitor design. Proc Natl Acad Sci USA (1997) 94:13420-13425.
49. Taing M, Keng Y-F, Shen K, Wu L, Lawrence DS, Zhang Z-Y: Potent and highly selective inhibitors of the protein tyrosine phosphatase 1B. Biochemistry (1999) 38:3793-3803.
50. Wang Q, Huang Z, Ramachandran C, Dinaut AN, Taylor SD: Naphthalenebis[α,α-difluoromethylenephosphonates] as potent inhibitors of protein tyrosine phosphatases. Bioorg Med Chem Lett (1998) 8:345-350.
51. Jia Z, Ye Q, Dinaut AN, Wang Q, Waddleton D, Payette P, Ramachandran C, Kennedy B, Hum G, Taylor SD: Structure of protein tyrosine phosphatase 1B in complex with inhibitors bearing two phosphotyrosine mimetics. J Med Chem (2001) 44:4584-4594. Discussion of the binding modes of bis-difluoromethylenephosphonate inhibitors.
52. Salmeen A, Andersen JN, Myers MP, Tonks NK, Barford D: Molecular basis for the dephosphorylation of the activation segment of the insulin receptor by protein tyrosine phosphatase 1B. Mol Cell (2000) 6:1401-1412.
53. Vetter SW, Keng YF, Lawrence DS, Zhang Z-Y: Assessment of protein-tyrosine phosphatase 1B substrate specificity using "inverse alanine scanning". J Biol Chem (2000) 275:2265-2268.
54. Sarmiento M, Puius YA, Vetter SW, Keng Y, Wu L, Zhoa Y, Lawrence DS, Almo SC, Zhang Z-Y: Structural basis of plasticity in protein tyrosine phosphatase 1B substrate recognition. Biochemistry (2000) 39:8171-8179. Discussion of the structural basis of plasticity in PTP1B substrate recognition.
55. Roller PP, Wu L, Zhang Z-Y, Burke TR Jr. Potent inhibition of protein-tyrosine phosphatase-1B using the phosphotyrosyl mimetic fluoro-O-malonyl tyrosine (FOMT). Bioorg Med Chem Lett (1998) 8:2149-2150.
56. Shen K, Keng YF, Wu L, Guo XL, Lawrence DS, Zhang Z-Y: Acquisition of a specific and potent PTP1B inhibitor from a novel combinatorial library and screening procedure. J Biol Chem (2001) 276:47311-47319. Development of the most potent and specific PTP 1B inhibitor to date.
57. Bleasdale JE, Ogg D, Palazuk BJ, Jacob CS, Swanson ML, Wang XY, Thompson DP, Conradi RA, Mathews WR, Laborde AL, Stuchly CW, Heijbel A, Bergdahl K, Bannow CA, Smith CW, Svensson C, Liljebris C, Schostarez HJ, May PD, Stevens FC, Larsen SD: Small molecule peptidomimetics containing a novel phosphotyrosine bioisostere inhibit protein tyrosine phosphatase 1B and augment insulin action. Biochemistry (2001) 40:5642-5654.
58. Larsen SD, Barf T, Liljebris C, May PD, Ogg D, O'Sullivan TJ, Palazuk BJ, Schostarez HJ, Stevens FC, Bleasdale JE: Synthesis and biological activity of a novel class of small molecular weight peptidomimetic competitive inhibitors of protein tyrosine phosphatase 1B. J Med Chem (2002) 45:598-622.
59. Burke TR Jr, Yao ZJ, He Z, Milne GWA, Li W, Zhang Z-Y, Voigt JH: Enantioselective synthesis of nonphosphorous-containing phosphotyrosyl mimetics and their use in the preparation of tyrosine phosphatase inhibitory peptides. Tetrahedron (1998) 54:9981-9994.
60. Iversen LF, Andersen HS, Branner S, Mortensen SB, Peters GH, Norris K, Olsen OH, Jeppesen CB, Lundt BF, Ripka W, Møller KB, Møller NP: Structure-based design of a low molecular weight, non-phosphorus, non-peptide, and highly selective inhibitor of protein-tyrosine phosphatase 1B. J Biol Chem (2000) 275:10300-10307.
61. Peters GH, Iversen LF, Branner S, Andersen HS, Mortensen SB, Olsen OH, Møller KB, Mollen NPH: Residue 259 is a key determinant of substrate specificity of protein-tyrosine phosphatases 1B and α. J Biol Chem (2000) 275:1821-18209.
62. Iversen LF, Andersen HS, Møller KB, Olsen OH, Peters GH, Branner S, Mortensen SB, Hansen TK, Lau J, Ge Y, Holsworth DD, Newman MJ, Møller NPH: Steric hindrance as a basis for structured-based design of selective inhibitors of protein tyrosine phosphatases. Biochemistry (2001) 40:14812-14820.
63. Andersen J, Mortensen OH, Peters GH, Drake PG, Iverson LF, Olsen OH, Jansen PG, Andersen HS, Tonks NK, Møller NPH: Structural and evolutionary relationships among protein tyrosine phosphatase domains. Mol Cell Biol (2001) 21:7117-7136.
64. You-Ten KE, Muise ES, Itie A, Michaliszyn E, Wagner J, Jothy S, Lapp WS, Tremblay ML: Impaired bone marrow microenvironment and immune function in T-cell protein tyrosine phosphatase-deficient mice. J Exp Med (1997) 186:683-693.
65. Iversen FL, Møller KB, Pedersen AK, Peters GH, Petersen AS, Andersen HS, Branner S, Mortensen SB, Møller NPH: Structure determination of T-cell protein tyrosine phosphatase. J Biol Chem (2002) in press. New structural data of TCPTP, the closest homolog of PTP1B.
66. Butler M, McKay RA, Popoff I, Gaarde W, Witchell D, Dean NM, Bhanot S, Monia BP: Specific inhibition of PTEN and PTP1B using antisense oligonucleotides normalizes plasma glucose in db/db mice. FASEB Summer Conference on Protein Phosphatases, Copper Mountain, CO, USA (2000):Abs 45.
67. Bhanot S, Butler M, Booten S, Mckay R, Murray S, Monia BP, Beck TW, Levin AA: Effects of a novel PTP1B antisense inhibitor (ISIS 113715) in cynomologous monkeys. Diabetes Mellitus: Molecular Mechanisms, Genetics and New Therapies Conference, Keystone, CO, USA (2002):Abs 202.
68. Malamas MS, Sredy J, Moxham C, Katz A, Xu W, McDevitt R, Adebayo FO, Sawicki DR, Seestaller L, Sullivan D, Taylor JR: Novel benzofuran and benzothiophene biphenyls as inhibitors protein tyrosine phosphatase 1B with antihyperglycemic properties. J Med Chem (2000) 43:1293-1310.
69. Malamas MS, Sredy J, Gunawan I, Mihan B, Sawicki DR, Seestaller L, Sullivan D, Flam BR: New azolidinediones as inhibitors of protein tyrosine phosphatase 1B with antihyperglycemic properties. J Med Chem (2000) 43:995-1010.
70. Wrobel J, Sredy J, Moxham C, Dietrich A, Li Z, Sawicki DR, Seestaller L, Wu L, Katz A, Sullivan D, Tio C, Zhang Z-Y: PTP1B inhibition and anti-hyperglycemic activity in the ob/ob mouse model of novel 11-arylbenzo[b]naphtho[2,3-d]furans and 11-arylbenzo[b]naphtho[2,3-d]thiophenes. J Med Chem (1999) 42:3199-3202.
71. Wrobel J, Li Z, Sredy J, Sawicki DR, Seestaller L, Sullivan D: Synthesis and PTP1B inhibition of novel 4-aryl-1-oxa-9-thiacyclopenta[b]fluorenes. Bioorg Med Chem Lett (2000) 10:1535-1538.
72. Wang S, Erbe D, Xing Y, Kung L, Li D, Harding K, Maylor R, Tobin JF: WAY144112: A novel insulin sensitizer with multiple mechanisms of action. Diabetes Mellitus: Molecular Mechanisms, Genetics and New Therapies Conference, Keystone, CO, USA (2002):Abs 241.
73. Tobin JF, Wang S, Klaman L, Xing Y, Kung L, Li D, Harding K, Maylor R, Steiner K, Jordan R, Erbe DV: Multiple mechanisms of action for the novel insulin sensitizer, Ertiprotafib. (2002) manuscript in preparation.
74. Burkey BF, Dong M, Wennogle L, Babb R, Dressman M, Islam A, Deacon R, Dragland C, Kaplan E, Tomesch J, Gao J: Pharmacogeonomic evaluation of a putative orally active PTP-1B inhibitor using ob/ob mice reveals an alternative mechanism of action. 62nd American Diabetes Association Annual Meeting, San Francisco, CA, USA (2002):Abs 138.
75. Inzucchi SE: Oral antihyperglycemic therapy for type 2 diabetes: Scientific review. J Am Med Assoc (2002) 287:360-372.
76. Mudaliar S, Henry RR: New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers. Annu Rev Med (2001) 52:239-257.
77. ABBOT LABORATORIES (Liu G, Szczepankiewicz BG, PEI Z, Xin Z, Oost TK, Janowick DA): Amino (oxo) acetic acid protein tyrosine phosphatase inhibitors. WO-00218323 (2002).
78. AMERICAN HOME PRODUCTS CORPORATION (Malamas MS, Adebayo F, Dollings PJ): Biphenyl sulfonyl aryl carboxylic acids useful in the treatment of insulin resistance and hyperglycemia. US-06221902 (2001).
79. AMERICAN HOME PRODUCTS CORPORATION (Dollings PJ, McDevitt RE, Adebayo FO): Furan, benzofurans and thiophene useful in the treatment of insulin resistance and hyperglycemia. US-06103708 (2000).
80. AMERICAN HOME PRODUCTS CORPORATION (Malamas MS, McDevitt RE, Adebayo FO): Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia. WO-09958518 (1999).
81. AMERICAN HOME PRODUCTS CORPORATION (Butera JA, Caufield CE, Graceffa RF, Greenfield A, Gundersen EG, Havran LM, Katz AH, Lennox JR, Mayer SC, McDevitt RE): 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia. WO-09961410 (1999).
82. AMERICAN HOME PRODUCTS CORPORATION (Wrobel JE, Dietrich AJ, Li Z): 11-aryl-benzo[b]naphtho[2,3-d]furans and 11-arylbenzo[b]naphtho[2,3-d]thiophenes useful in the treatment of insulin resistance and hyperglycemia. US-06110962 (2000).
83. AMERICAN HOME PRODUCTS CORPORATION (Dollings PJ, Dietrich AJ, Wrobel JE): Naphtho[2,3-b]heteroar-4-yl derivatives. WO-09958522 (1999).
84. AMERICAN HOME PRODUCTS CORPORATION (Kees KL): 2-(Acylaminothiazole-4-yl)acetic acid derivatives. WO-09958514 (1999).
85. AMERICAN HOME PRODUCTS CORPORATION (Li Z): 4-aryl-1-oxa-9-thia-cylopenta[b]fluorenes. US-06281238 (2001).
86. AMERICAN HOME PRODUCTS CORPORATION (Li Z, Wrobel JE): 4-Aryl-1-oxa-9-thia-cyclopenta[b]fluorene. US-20010020037 (2001).
87. AMERICAN HOME PRODUCTS CORPORATION (Malamas MS): Aryloxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia. US-06110963 (2000).
88. AMERICAN HOME PRODUCTS CORPORATION (Malamas MS): Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia. WO-09958511 (1999).
89. AMERICAN HOME PRODUCTS CORPORATION (Wrobel JE, Dietrich AJ, Li Z): 11-aryl-benzo[b]naphtha [2,3-d] furans and 11-arylbenzo[b]naphtho[2,3-d]thiophenes useful in the treatment of insulin resistance and hyperglycemia. WO-09958521 (1999).
90. AMERICAN HOME PRODUCTS CORPORATION (Butera JA, Caufield CE, Graceffa RF, Greenfield A, Gunderson EG, Havran LM, Katz AH, Lennox JR, Mayer SC, McDevitt RE): 2,3,5-Substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia. WO-09961410 (1999).
91. AMERICAN HOME PRODUCTS CORPORATION (Wrobel JE, Dietrich AJ, Antane MM): Benzothiophenes, benzofurans and indoles useful in tfle the treatment of insulin resistance and hyperglycemia. WO-09961435 (1999).
92. MERCK FROSST GANADA & CO/BANYU & CO/BANYU PHARM CO LTD (Bayly C, Ohkubo M): Sulfur substituted aryldifluoromethyl phosphonic acids as PTP-1B inhibitors. WO-00170754 (2001).
93. MERCK FROSST CANADA & CO (Li CS, Lau CK, Therien M, Gauthier JY, Bayly C, Dufresne C, Fortin R, Leblanc Y, Roy P, Wang Z): Sulfur substituted aryldifluoromethyl-phosphonic acids as PTP-1B inhibitors. WO-00170753 (2001).
94. MERCK FROSST CANADA & CO (Lau CK, Bayly C, Gauthier JY, Leblanc Y, Li CS, Roy P, Therien M, Wang Z): Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B). WO-00146203 (2001).
95. MERCK FROSST CANADA & CO (Leblanc Y, Dufresne C, Gauthier JY, Young R): Aromatic phosphonates as protein tyrosine phosphatase 1 B (PTP-1 B) inhibitors. WO-00146204 (2001).
96. MERCK FROSST CANADA & CO (Leblanc Y, Dufresne C, Gauthier JY, Lau CK, Li CS, Roy P, Thieren M, Scheigetz J, Wang Z): Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1 B). WO-00146206 (2001).
97. MERCK FROSST CANADA & Co (Leblanc Y, Lau CK, Dufresne C, Li CS, Roy P, Wang Z, Scheigetz J, Boyd M): Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B). WO-00146205 (2001).
98. MERCK FROSST CANADA & CO (Leblanc Y, Dufresne C, Wang Z, Li CS, Gauthier JY, Therien M, Lau CK, Roy P): Phosphonic acids derivatives as inhibitors of PTP-1B. WO-00017211 (2000).
99. MERCK FROSST CANADA & CO (Kennedy B, Payette P, Gresser M, Ramachandran C, Tremblay ML, Elchebly M): Protein tyrosine phosphatase-1 B (PTP-1 B) deficient mice and uses thereof. WO-00006712 (2000).
100. MERCK FROSST CANADA & CO (Leblanc Y, Dufresne C, Roy P, Wang Z): Phosphonic and carboxylic acid derivatives as inhibitors of protein tyrosine phosphatase-1B (PTP-1B). WO-00069889 (2000).
101. MERCK FROSST CANADA & CO (Leblanc Y, Claude D, Roy P, Wang Z): Phosphonic and carboxylic acid derivatives as inhibitors of protein tyrosine phosphatase-1B (PTP1B). US-06365592 (2002).
102. MORPHOCHEM AG (Liu Y, Wang S, Zhang Z-Y): Process for obtaining inhibitors/activators of an enzyme. WO-00164939 (2001).
103. NOVO NORDISK AS (Andersen HS, Hansen TK, Iverson LF, Lau J, Møller NPH, Olsen OH, Axe FU, Ge Y, Holsworth DD, Jones TK, Judge LM, Ripka WC, Shapira BZ, Uyeda RT): Method of inhibiting protein tyrosine phosphatase 1B and/or T-cell protein tyrosine phosphatase and/or other PTPases with an asp residue at position 48. WO-00117516 (2001).
104. NOVO NORDISK AS (Hansen TK, Lau J, Møller NPH, Olsen OH, Axe FU, Bakir F, Ge Y, Holsworth DD, Judge LM, Newman MJ, Uyeda RT, Shapira BZ): Modulators of protein tyrosine phosphatases (PTPases). WO-00204458 (2002).
105. NOVO NORDISK AS (Andersen HS, Jones TK, Holsworth DD): Modulators of protein tyrosine phosphatases (PTPases). US-200200019412 (2002).
106. NOVO NORDISK AS (Lone J, Andersen HS, Olsen OH, Judge LM, Holsworth DD, Bakir F, Axe FU, GE Y): Modulators of protein tyrosine phosphatases (PTPases). US-20020002199 (2002).
107. NOVO NORDISK AS (Andersen HS, Hansen TK, Lau J, Møller NPH, Olsen OH, Axe FU, Ge Y, Holsworth DD, Jones TK, Judge LM, Ripka WC, Shapira BZ, Uyeda RT): Modulators of protein tyrosine phosphatases (PTPases). WO-00119831 (2001).
108. NOVO NORDISK AS (Andersen HS, Hansen TK, Lau J, Møller NPH, Olsen OH, Axe FU, Ge Y, Holsworth DD, Jones TK, Judge LM, Ripka WC, Shapira BZ, Uyeda RT): Modulators of protein tyrosine phosphatases (PTPases). WO-00119830 (2001).
109. ONTOGEN CORPORATION (Ritcher LS, Andersen HS, Vagner J, Jeppesen CB, Møller NPH, Branner S, Su J, Bakir F, Judge LM): Modulators of protein tyrosine phosphatases (PTPases). WO-09946236 (1999).
110. ONTOGEN CORPORATION (Andersen HS, Jones TK, Holsworth DD): Modulators of protein tyrosine phosphatases (PTPases). WO-09946268 (1999).
111. ONTOGEN CORPORATION (Møller NPH, Andersen HS, Iversen LF, Olsen OH, Branner S, Holsworth DD, Bakir F, Judge LM, Axe FU, Jones TK, Ripka WC, Ge Y, Uyeda RT): Modulators of protein tyrosine phosphatases (PTPases). WO-09946267 (1999).
112. ONTOGEN CORPORATION (Jeppesen L, Andersen HS, Olsen OH, Judge LM, Holsworth DD, Bakir F, Axe FU, Ge Y): Modulators of protein tyrosine phosphatases (PTPases). WO-09946244 (1999).
113. ONTOGEN CORPORATION (Andersen HS, Branner S, Jeppesen CB, Møller NPH, Sarshar S, Mjalli A): Modulators of protein tyrosine phosphatases (PTPases). WO-09915529 (1999).
114. ONTOGEN CORPORATION (Mjalli A, Sarshar S, Cao X, Bakir F): Modulators of proteins with phosphotyrosine recognition units. US-05965558 (1999).
115. PHARMACIA & UPJOHN COMPANY (Larsen SD, May PD, Bleasdale JE, Liljebris C, Schostarez HJ, Barf T): Inhibitors of protein tyrosine phosphatase. US-06353023 (1998).
116. PHARMAClA & UPJOHN COMPANY (Larsen SD, May PD, Bleasdale JE, Liljebris C, Schostarez HJ, Barf T, Nilsson M): Inhibitors of protein tyrosine phosphatase. WO-00053583 (2000).
117. TAKEDA CHEMICAL INDUSTRIES LTD (Matsumoto T, Katayama N, Mabuchi H): Tyrosine phosphatase inhibitors. WO-00190067 (2001).
118. THE GOVERNMENT OF THE UNITED STATES OF AMERICA (Burke TR Jr, Akamatsu M, Kole HK, Yan X, Roller PR, Ye B): O-Malonyltyrosyl compounds, O-malonyltyrosyl compound-containing peptides and uses thereof. WO-9630332 (1996).
119. UNIVERSITY OF CALIFORNIA (Olefsky JM): Method for treatment of insulin resistance. WO-09732595 (1997).